PT-141 and Melanotan II are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
One family, two receptor strategies
PT-141 and Melanotan II are close relatives — in fact, PT-141 was engineered directly from Melanotan II. Both are synthetic cyclic heptapeptide analogues of α-melanocyte-stimulating hormone (α-MSH), and both share the same core cyclic backbone. What separates them is not chemistry so much as breadth: Melanotan II activates the whole melanocortin receptor family, while PT-141 was deliberately narrowed to focus its action. That single design choice explains almost every downstream difference in how the two are studied. Here we put them side by side.
| PT-141 | Melanotan II | |
|---|---|---|
| Class / peptide type | Cyclic melanocortin agonist (α-MSH analogue) | Cyclic melanocortin agonist (α-MSH analogue) |
| Primary target | MC3R / MC4R — comparatively selective, spares MC1R | MC1R · MC3R · MC4R · MC5R — non-selective |
| Structure / MW | C-terminal acid; ~1025 Da | C-terminal amide; ~1024 Da |
| Approx. half-life | ~2 hours | ~33 hours (extended) |
| Main research focus | Libido / central sexual behaviour, CNS pharmacology | Pigmentation / photoprotection (arousal a noted secondary effect) |
| Regulatory status | FDA-approved (Vyleesi, 2019) for premenopausal HSDD | Unregulated — no approved medicinal product |
PT-141: the selective descendant
PT-141 (bremelanotide) is the more refined of the pair. It was created from Melanotan II by stripping the C-terminal amide and cyclising the backbone, a modification that trims the molecule's activity down to the melanocortin-3 and melanocortin-4 receptors — with its greatest functional effect at MC4R — while sparing the MC1R receptor responsible for pigmentation. In practical research terms, that means PT-141 is studied for its central effects without the skin-darkening that accompanies broader melanocortin agonism.
Its research focus is squarely on the central nervous system. PT-141 engages MC4R-positive POMC neurons in the hypothalamus and modulates dopaminergic activity in the medial preoptic area — circuitry most associated with sexual motivation in published rodent work. That mechanism is reflected in its regulatory standing: PT-141 is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, making it the only member of this pair to carry a mature clinical dataset. Its half-life is short, on the order of two hours, consistent with an agent studied for an acute, on-demand central effect rather than sustained exposure. Researchers sourcing the compound can buy PT-141 UK as research-grade material with a COA.
Melanotan II: the broad-spectrum parent
Melanotan II (MT-II, MT-2) is the older, less selective molecule — developed at the University of Arizona in the 1980s as a photoprotection research compound. Where PT-141 was narrowed, MT-II is deliberately broad: it activates all four functional melanocortin receptors, MC1R, MC3R, MC4R and MC5R. MC1R activation drives the eumelanin switch in melanocytes, the pathway behind its long-standing pigmentation and tanning research role, while its MC3R/MC4R activity engages the same appetite and sexual-motivation circuitry that PT-141 targets — here as a secondary rather than a primary effect.
Two structural features set MT-II apart. It retains the C-terminal amide that PT-141 removes, and its intact cyclic backbone confers substantial metabolic stability. Together these give it a markedly longer half-life — around 33 hours versus PT-141's ~2 hours — long enough to support once-daily research dosing. That breadth comes at a cost in specificity: MT-II's non-selective profile makes it the standard research probe for melanocortin biology as a whole, but it has never advanced to an approved medicinal product and remains an unregulated research compound. For the full receptor and mechanism detail, see the Melanotan II knowledgebase page, or buy Melanotan II UK research material directly.
What the differences mean in a research context
The two compounds are best understood as a selectivity experiment run on a single scaffold. Start with the broad parent, remove one structural group, and you convert a whole-family melanocortin agonist into a comparatively MC4R-focused one — and the research profile shifts with it. Melanotan II's MC1R activity puts pigmentation front and centre; PT-141's MC1R-sparing design removes that arm entirely and leaves the central MC4R signal to dominate.
That distinction matters for how each is deployed. If the research question is about pigmentation, photoprotection or broad melanocortin coverage, MT-II's non-selective profile and long half-life are the point. If the question is about central arousal circuitry in isolation — MC4R signalling without the confound of skin-darkening or the wider receptor cross-talk — PT-141 is the cleaner probe, which is precisely why it, and not its parent, became a regulated clinical product. The half-life gap reinforces the split: MT-II's ~33 hours suits sustained exposure studies, while PT-141's short window fits acute, on-demand paradigms. It is also worth noting that the two are sometimes studied together where both broad pigmentation and central arousal effects are the combined research aim.
The bottom line
Same lineage, different emphasis. Melanotan II is the broad, non-selective, pigmentation-focused parent with a long half-life and no regulatory approval; PT-141 is its MC4R-selective, libido-focused descendant with a short half-life and a mature FDA dataset. Neither is "better" in the abstract — they answer different research questions. For research-grade material, see our dedicated pages to buy PT-141 UK and buy Melanotan II UK, each ≥99% purity with a COA.